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Targeting therapeutic genes to the liver is essential to improve gene therapy protocols of hepatic
diseases and of some hereditary disorders. Transcriptional targeting can be achieved using
liver-specific promoters. In this study we have made chimeric constructs combining promoter and
enhancer regions of the albumin, 1-antitrypsin, hepatitis B virus core protein, and hemopexin
genes. Tissue specificity, activity, and length of gene expression driven from these chimeric
regulatory sequences have been analyzed in cultured cells from hepatic and nonhepatic origin as
well as in mice livers and other organs. We have identified a collection of liver-specific promoters
whose activities range from twofold to less than 1% of the CMV promoter in human hepatoma
cells. We found that the best liver specificity was attained when both enhancer and promoter
sequences of hepatic genes were combined. In vivo studies were performed to analyze promoter
function during a period of 50 days after gene transfer to the mouse liver. We found that among
the various chimeric constructs tested in this work, the 1-antitrypsin promoter alone or linked to
the albumin or hepatitis B enhancers is the most potent in directing stable gene expression in liver
cells.
Key Words: transcriptional targeting, gene therapy, liver-specific promoters,
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INTRODUCTION
The liver fulfils a great variety of essential functions in the
body, including the synthesis of proteins involved in me-
tabolism, hemostasis, and protection against infection.
Many genetic diseases, such as hemophilia A or B, orni-
thine transcarbamylase deficiency, familial hypercholes-
terolemia, or 1-antitrypsin deficiency, are associated
with altered gene expression in the liver. Although some
of these defects can be treated by infusion of the deficient
protein, this is expensive, carries a risk of toxicity, and
works only temporarily. A simple alternative could be the
use of gene therapy to express a functional gene in the
liver to replace a needed protein or to block the expres-
sion of an altered gene product. Transduction of hepatic
cells with appropriate genes, such as immunostimulatory
cytokines, can also be useful to induce immune responses
against viral hepatitis or liver neoplasms [1,2].
Gene transfer into mammalian hepatocytes has been
performed using both ex vivo and in vivo procedures. The
ex vivo approach requires harvesting of the liver cells, in
vitro transduction with long-term expression vectors, and
reintroduction of the transduced hepatocytes into the
portal circulation [3,4]. In vivo targeting has been done by
injecting DNA or viral vectors into the liver parenchyma,
hepatic artery, or portal vein. Adenoviral vectors, even
when administered systemically, target mainly the liver
in mice [5] but can also infect lung and skeletal muscle
[6,7]. Moreover, the liver specificity of adenovirus has not
yet been demonstrated in humans.
Another method to localize gene expression is by tran-
scriptional targeting. The use of proper liver-specific tran-
scriptional elements should restrict the expression of a
therapeutic gene to hepatocytes. Some promoters that are
active mainly in the liver have been already used for
cell-specific gene delivery [8,9]. The major disadvantages
for their use in gene therapy are (i) the big size, since
many vectors have a restricted cloning space, and/or (ii)
the low activity compared to cytomegalovirus (CMV) or
long terminal repeat (LTR) promoter sequences, widely
used in gene therapy protocols. In an attempt to construct
promoters of high liver specificity and activity, we have
selected hepatospecific transcriptional sequences using
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the following criteria: (i) short size, (ii) known regulatory
factors, (iii) expression independent of tight metabolic or
hormonal control, and (iv) non-species-specificity.
The liver promoters used in this study were from
mouse albumin, human 1-antitrypsin, and hemopexin
genes (Fig. 1A). The albumin is an abundant protein in
the adult serum, it is mostly expressed in the liver and it
is regulated at the transcriptional level [10]. The albumin
promoter shows high homology between different spe-
cies, including rat, chicken, frog, mouse, and human
[11,12]. The human 1-antitrypsin (AAT) gene has been
extensively characterized [13–15]. AAT is one of the major
proteinase inhibitors in serum and it is synthesized
mainly in hepatocytes, although it is also expressed by
macrophages during inflammation [16]. Hepatocytes and
macrophages transcribe the same coding region of the
AAT gene from promoters that are 2 kb apart [17]. The
hemopexin is a heme-binding plasma glycoprotein se-
creted only by the liver whose synthesis is increased dur-
ing acute infections [18].
The enhancer regions employed in this work were the
distal mouse albumin regulatory region and the enhancer
II (EII) of the human hepatitis B virus (HBV) (Figs. 2A and
3). The far-upstream enhancer (10.5 to 8.5 kb) of the
albumin gene is required for full hepatocyte-specific ex-
pression in transgenic mice [19] and is able to stimulate
promoter activity in cultured hepatocytes and in hepa-
toma cells [20,21]. The EII is responsible for the liver-
specific transcription of pregenomic 3.5-kb-long RNA that
codes for the core protein and serves as template for viral
DNA synthesis [22,23]. This enhancer has been previously
used to stimulate activity of the CMV minimal promoter
(CMVm) in the context of adenoviral vectors [7]. Even if
the hybrid promoter was as strong as the CMV whole
regulatory sequence in mouse liver and EII-mediated en-
hancement was liver specific, expression in other tissues
was still detected [7,24].
Our goal was to construct a collection of highly specific
chimeric promoters that have different activities in he-
patic cells, but low or no function in extrahepatic tissues.
Adequate liver expression of a transgene can then be
tuned by choosing the right enhancer–promoter combi-
nation. In this study we have compared activity and spec-
ificity of albumin, AAT, and hemopexin promoters, to-
gether with the nonspecific widely used SV40 and CMV
promoters. We have analyzed the function and specificity
of hepatic enhancers combined with specific and nonspe-
cific promoter sequences in culture cells and in Balb/C
and C57BL/6 mice. The broader range of activity and best
specificity were achieved when both liver promoter and
enhancers were combined. Some of these constructs were
also able to conduct stable gene expression in a long-term
study, making them good candidates to be used in gene
therapy protocols.
RESULTS
Construction of Reporter Plasmids Containing the
Liver Promoters: In Vitro Comparative Study
The 5 flanking region of the albumin gene that confers
promoter activity and liver-specific expression is limited
to about 170 bp [10]. Deletions, mutations, and foot-
printing analysis with nuclear extracts or purified proteins
have allowed the identification of transcription activators
involved in promoter function (Fig. 1A) [11,25–27]. We
cloned the region encompassing nucleotides180 to16
(relative to the cap site) of the mouse albumin gene (Palb)
to drive luciferase expression in the reporter plasmid
pGL3 basic. A tissue-specific element (TSE) required for
liver function of the AAT promoter was identified be-
tween nucleotides 137 and 37. TSE is involved in
positive and negative regulation in hepatic and nonhe-
patic cells, respectively [13,15,28]. The sequence from
261 to 44 contains a distal region (DRI) required for
whole promoter activity. Both TSE and DRI were cloned
in the pGL3 basic reporter vector (Pa1AT) (Fig. 1A). DNA
binding sequences for nuclear proteins involved in he-
mopexin liver specificity and IL-6 induction have been
identified in position 120 to 104 of the gene [29].
Sequence from 175 to 22 of the human hemopexin
promoter, necessary to direct cell-specific transcription
[18], was isolated and cloned in pGL3 basic vector (Phpx)
(Fig. 1A). These pGL3 derivatives were used to transfect
well-differentiated hepatoma and hepatocarcinoma cells
from different origins: human HepG2 and Hep3B, mouse
Hepa1-6, and rat H35. All of them express considerable
levels of albumin, AAT, and hemopexin, as a guarantee of
hepatocyte differentiation [13,30]. As negative controls
we used human nonliver HeLa and HEK293 cells, which
do not express these genes [13,31]. To control transfec-
tion efficiency and cell recovery, which may vary between
experiments and cell lines, we cotransfected the pGL3
derivatives with a plasmid that expresses Renilla luciferase
under the control of the SV40 promoter and all the results
have been corrected for Renilla luciferase expression (see
Materials and Methods). We have also compared the ac-
tivities of the liver promoters with those from the strong
CMV promoter (Fig. 1B). To determine the effects of the
enhancers on the universal CMV and early SV40 promot-
ers, we studied the expression from both, with (CMV and
SV40) and without (CMVm and SV40m) their enhancer
regions.
CMV was the strongest promoter in all cell types,
showing an expression 4- to 40-fold higher than SV40. As
expected, promoter strength decreased when the minimal
CMV and SV40 promoters were used, but expression lev-
els were well above background. This reduction was de-
pendent both on the promoter and on the cells, from 3 to
12 times in the case of SV40 or 14- to 80-fold for CMV.
Unlike CMV and SV40 promoters, which were active in
cells from hepatic and nonhepatic origin, Palb, Phpx, and
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FIG. 1. Activity of universal and liver-specific promoters (A) Schematic structure of the liver promoters. Specific (DBP, D-site binding protein; C/EBP, CCAAT enhancer
binding protein  or ; HNF, hepatocyte nuclear factor; IL-6DBP, liver-specific IL-6-dependent DNA binding protein) and nonspecific (NF-1, nuclear factor 1; NF-Y, CAAT
binding protein; AP-1) activating transcription factors that bind to each regulatory sequence are indicated for the albumin, Palb [26]; 1-antitrypsin, Pa1AT [14,15]; and
hemopexin, Phpx [18,29] promoters. Binding regions of putative repressor factors present in nonhepatic cells are depicted [11,18,28]. Coordinates with respect to the
cap site and size (base pairs) of each sequence are indicated. Regulatory elements are shown: DE, distal element; PE, proximal element; TSE, tissue-specific element;
IL-6RE, interleukin-6-response element; TATA box. (B) Promoter activity in liver and nonliver cells. Hepatic (HepG2, Hep3B, Hepa1-6, H35) and nonhepatic (HeLa,
HEK293) cell lines were transiently transfected with plasmids containing the indicated promoters. Luciferase expression from the liver-specific promoters was compared
to the expression driven by the immediate-early cytomegalovirus promoter (CMV), early SV40 promoter, and CMVm and SV40m, which lack enhancer regions. The
mean (two independent experiments) of luciferase expression relative to the maximum (100%) CMV activity is represented. The amount of luciferase for CMV promoter
was 1965.22 42.74, 1033.60 139.89, 585.90 8.72, 18.24 0.56, 2112.12 78.17, and 9427.15 505.91 for HepG2, Hep3B, Hepa1-6, H35, HeLa, and 293
cells, respectively. Values are expressed as means  SD. An amplified view of the activity of Palb and Phpx is shown in the small box.
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Pa1AT were functional only in liver cells. Of the three
liver-specific promoters tested, Pa1AT was the strongest,
yielding almost 40% of CMV activity in HepG2 cells. Of
note, as shown in the small box of Fig. 1B, Palb and Phpx
exhibit a marked liver specificity although the expression
in hepatic cells is low, even lower than the minimal
nonspecific promoters (CMVm and SV40m).
Effect of the EII Liver-Specific Sequence in the
Enhancement of Hepatic and Universal Promoters
The HBV EII enhancer has been well characterized by
site-directed mutagenesis and was limited to a 155-bp
fragment [22,23,32,33] (Fig. 2A). Lo¨ser and co-workers
[24] used a construct composed of the EII plus the pro-
moter of viral core protein of HBV (two elements that are
adjacent in the viral genome [34,35]) and showed that
these regulatory sequences were able to augment the ac-
tivity of the universal CMVm promoter in liver cells. This
construct showed, however, some nonspecific activity in
cells from nonliver origin [7,24]. To determine whether
this nonspecificity was due to the EII element or to the
CMVm sequence, we have made several promoter con-
structs to compare their activity in different cells. Two
reporter plasmids were prepared, one containing only the
29-bp core promoter (Pcore) and the other containing EII
fused to Pcore (EIIPcore). We also generated a vector link-
FIG. 2. Influence of hepatitis B enhancer II on promoter activity. (A) The EII region is shown. Binding regions for hepatic (C/EBP; HNFs; HLF, hepatic leukemia
factor; FTF, fetoprotein transcription factor; RXR–PPAR, retinoid X receptor –peroxisome proliferator-activated receptor  heterodimer) and ubiquitous (Sp1)
transcription factors are indicated. These activating factors are required for core protein transcription and pregenomic RNA synthesis [32,33]. The transcriptional
suppressor E4BP4 binding site is indicated. This protein is present mainly in nonhepatic cells [49]. P, core promoter. Coordinates are given according to Cheng
et al. [34]. (B) The activity of Pcore and CMVm promoters with (EIICMVm, EIIPcore) or without enhancer II sequence was analyzed in liver cells. (C) Luciferase
expression from the same promoters was analyzed in nonliver cells. The percentage with respect to CMV activity is represented and the absolute value of
luciferase expression driven by the CMV promoter is given in the legend to Fig. 1.
FIG. 3. The mouse albumin enhancer (Ealb). This se-
quence contains three functional regions (R1–R3). Liver-
specific transcription factors (eH-TF, C/EBP, and HNF-3)
and NF-1 binding places are indicated [20,50]. R3 acts as
a negative element [20], hence it was removed from our
construct (short fragment). Coordinates with respect to
the transcriptional start point (arrow) are shown. P, al-
bumin promoter.
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ing EII directly to CMVm (EIICMVm). All these con-
structs, together with CMV and CMVm, were analyzed for
luciferase expression. Results are shown in Figs. 2B and
2C. We observed that EII was able to markedly enhance
CMVm activity in liver cells (up to 58 times in HepG2
cells) and also to a lesser extent in nonhepatic cells (up to
fourfold). Activity of Pcore alone was liver specific but
very low. EII was also able to stimulate the function of
Pcore in hepatic human cells from 5.4 (Hep3B) to 106
(HepG2) times (Fig. 2B), but did not affect expression in
nonliver cells (Fig. 2C). From these results we conclude
that promoter enhancement using EII can be achieved
without loss of specificity. Moreover, both the promoter
and the enhancer sequences need to be liver specific to
reduce maximally extrahepatic gene expression.
Construction of Chimeric Liver-Specific Promoters
To increase gene expression levels in hepatic tissue we
decided to use strong liver-specific promoters bound to
specific enhancers. The far-upstream mouse albumin gene
enhancer (Ealb) contains both positive and negative reg-
ulatory regions and the DNA binding sites for liver-spe-
cific factors [19,20]. We used the positive regions of 370-
bp-long (Fig. 3) for the design of new promoter
constructs. We have fused Ealb or EII with the three liver
promoters shown in Fig. 1 (Palb, Pa1AT, and Phpx) in all
the possible combinations (Fig. 4A). The activity relative
to CMV of each chimera or of promoters alone is repre-
sented in Fig. 4B. Western blot analysis to detect the
luciferase protein driven by each construct in HepG2 cells
has been carried out from the most representative samples
to visualize and confirm the luciferase activity observed
(Fig. 4C). The results show that both enhancers work in
liver cells, but not in HeLa or 293 cells. EII was able to
stimulate expression from all three promoters: Palb was
enhanced up to 253-fold, Phpx up to 16-fold, and Pa1AT
up to 6.2-fold. On the other hand, Pa1AT was the only
promoter able to be enhanced by the albumin distal se-
quence, suggesting a minimum requirement of promoter
activity for the function of Ealb. In contrast to Pa1AT,
Palb and Phpx were practically unmodified by Ealb both
in hepatic and in nonliver cells. Interestingly, Ealb–Pa1AT
fusion was less active than Pa1AT alone in 293 and HeLa
cells, suggesting a possible role for inhibitors acting on
this enhancer in nonhepatic cells (Fig. 4B, small box).
In summary, if we order these promoter–enhancer se-
quences in a decrescent order of expression, the strongest
would be EII-Pa1AT, then Ealb-Pa1AT and EII-Palb fol-
lowed by EII-Phpx, Pa1AT, and Phpx. In all cases, the level
of expression in nonliver cells driven by them was very
low, indicating that combining liver transcriptional reg-
ulatory sequences is a good strategy for engineering liver-
specific promoters. Different expression levels observed in
the hepatic cells of various species could be due to varying
amounts of required transcription factors, as well as to the
presence or absence of other factors (i.e., p53) that could
influence gene expression. Additionally, promoter activ-
ity could be affected by the degree of differentiation of
each cell type [25,36].
In Vivo Study of the Activity of Chimeric Promoters
in the Liver and Duration of Gene Expression Driven
by These Regulatory Sequences
Administration of naked plasmid DNA by the hydrody-
namics-based system has been demonstrated to be an
efficient and rapid method for in vivo comparative studies
[37,38]. With this procedure and using 20 g of a -ga-
lactosidase reporter plasmid we have confirmed a trans-
fection efficiency between 10 and 20% (data not shown),
similar to that previously reported by other authors
[37,39,40]. In our study we have used this methodology
to analyze the expression driven by each of the most
representative promoters: EII-Pa1AT, Ealb-Pa1AT, EII-
Palb, EII-Phpx, Pa1AT, Ealb-Phpx, and Phpx, together
with the CMV and EIICMVm that served as controls. We
injected plasmids into Balb/C mice, prepared liver ex-
tracts, and measured luciferase activity. To ensure that
DNA uptake was comparable in all cases, we isolated total
DNA from livers of treated animals and detected plasmid
DNA by Southern blot analysis (Fig. 5A). Similar amounts
of DNA were observed in most of the samples obtained
from three representative mice. Differences, likely attrib-
utable to animal-to-animal variation or manipulation,
were comparable in all groups of animals. According to
the luciferase expression data obtained 6 h postinjection
of the plasmids (Fig. 5B), we could divide the assayed
promoters into three statistically significant groups: (i)
the highly active, represented by CMV, EII-Pa1AT, EII-
CMVm, and Ealb-Pa1AT; (ii) the moderately active, EII-
Palb, EII-Phpx, and Pa1AT (P  0.05); and (iii) the poorly
active, Ealb-Phpx and Phpx (P  0.001). In all cases, even
in the last group, a considerable level of gene expression
was observed. These in vivo data are in good agreement
with the results observed in culture cells (see above).
Duration of promoter activity was then tested in
C57BL/6 mice using the AAT gene as reporter. Serum
levels of AAT driven by each tested promoter were mea-
sured every 2 to 7 days (Fig. 5C). During the steady state
(after the initial upsurge of gene expression following
hydrodynamic administration of the plasmids) Phpx ac-
tivity decreased rapidly with time, while Pa1AT alone or
combined with EII and Ealb was more stable. These three
sequences, which were the most powerful in the long-
term study, allowed the obtainment, at day 50, of serum
levels of the secretable reporter protein of 70, 30, and 20
g/ml with Ealb-Pa1AT, EII-Pa1AT, and Pa1AT, respec-
tively. Although initially EII-Pa1AT showed the highest
activity, after 3 weeks it tended to decrease, to reach
values similar to those of Pa1AT alone, suggesting a pos-
sible inactivation of the EII viral enhancer.
Interestingly, EII-Phpx activity decreased about 20
times between days 1 and 16 but remained stable until
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day 50, indicating that in this promoter context the EII
sequence was active and was able to stabilize hpx pro-
moter function. EII-Palb showed activity and long-term
behavior almost identical to those of EII-Phpx (not
shown). With respect to the CMV promoter we observed
a progressive diminution of its activity with time (Fig.
5C). The values of the secretable reporter protein at day 50
(about 2 g/ml) were comparable for these three se-
quences (CMV, EII-Palb, and EII-Phpx).
Analysis of the Activity of Chimeric Promoters in
Extrahepatic Tissues
To test promoter specificity, we next studied the activity
of the regulatory sequences in organs other than the liver.
Transgene expression using the hydrodynamics-based
gene transfer method has been described in lung, spleen,
kidney, and heart [39] and thus these organs were ex-
tracted and analyzed for luciferase activity. Low levels of
expression were observed with each liver-specific con-
struct compared to the CMV promoter (Table 1). CMV
was more active in kidney than in the three other organs,
had similar activity in lung and spleen, and produced
little expression in heart. The activity observed with EII-
CMVm was 10 times less than with CMV in heart, but
only 3 times less in spleen. Combinations of liver-specific
enhancers and promoters yielded activities close to back-
ground levels, making it difficult to differentiate from the
basal expression coming from the pGL3basic vector alone
(not shown). In general, we found that the strength of a
promoter in the liver is proportional to its extrahepatic
functionality.
Since hydrodynamics gene delivery is more effective in
transfecting hepatocytes than other tissues [39] we de-
cided to use polyethylenimine (PEI) as vector to deliver
FIG. 4. Activity and specificity of chimeric promoters. (A) Constructed promoter/enhancer fusions. Albumin (Palb), 1-antitrypsin (Pa1AT), and hemopexin
(Phpx) promoter sequences have been fused to EII and Ealb regions in all possible combinations to drive luciferase expression. (B) Liver and nonliver cells were
transiently transfected with the indicated plasmids. Means  SD of luciferase expression driven from the chimeric promoters relative to CMV activity (100%) are
represented. The values of ng luciferase/mg total cell protein obtained with the CMV promoter in each cell line are given in the legend to Fig. 1. An amplified
view of promoter activity in HeLa and HEK293 cells is shown in the small box. (C) Detection of luciferase protein in HepG2 cells. Cells were transfected as above
and luciferase detection was performed by Western blot analysis. Luc, pure luciferase (2 ng) and () nontransfected cells. Arrow indicates the position of luciferase
protein.
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the plasmid constructs into the lung [41]. Southern blot
analysis of lung extracts demonstrated similar plasmid
uptake efficiency with both CMV and EII-Pa1AT (Fig. 6A).
As shown in Fig. 6B, luciferase expression in the lung from
all chimeric promoters was three orders of magnitude
lower than from CMV. This low activity was similar to
that observed in the previous experiment (Table 1). This
indicates that when we achieve a high in vivo transfection
efficiency of extrahepatic tissues, the specificity of liver-
specific promoters is manifested more clearly. Inciden-
tally, we observed, in agreement with other reports [24],
that EIICMVm, which manifested the highest activity in
all nonhepatic organs analyzed, was only 20 times less
active than CMV in lung (Fig. 6B).
FIG. 5. In vivo activity of chimeric promoters. (A) 20 g of plasmids containing the selected promoters was transferred into Balb/C mice (n 	 4–6) by
hydrodynamics intravenous injection. Total DNA was recovered from livers of untreated () and treated mice 6 h postinjection and digested with KpnI. 15 g
of DNA was then loaded on an agarose gel and plasmid bands were detected by Southern blot. 10 ng of CMV-luc plasmid (pCMV) was used as positive control.
(B) Luciferase activity (relative light units) was measured in the same liver extracts. Mean  SD of each experiment is represented. Statistical analysis performed
with SPSS version 9.0 software showed significant differences between the groups *P  0.05 and ***P  0.001. (C) Long-term expression study. Plasmids
containing the AAT gene driven by the indicated promoters were administrated to C57BL/6 mice (n 	 5). Blood samples were collected at the indicated days
and concentration of AAT in serum was determined. Day 0 corresponds to 6 h after DNA injection.
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DISCUSSION
Restriction to the liver of the synthesis of adequate
amounts of a therapeutic protein may be advantageous
for the effective treatment of inherited or acquired dis-
eases. The fact that the liver produces a great variety of
essential proteins that are not synthesized by other organs
or tissues indicates the existence of a strict regulation of
such genes like albumin, 1-antitrypsin, and hemopexin.
In the present work we have selected the transcriptional
regulatory sequences of these genes in an attempt to de-
fine a set of liver-specific promoters with different activi-
ties for application in gene therapy protocols.
We observed that the in vitro expression driven by each
promoter alone was specific but substantially lower than
that of the ubiquitously active CMV promoter and en-
hancer, which is commonly used to construct gene ther-
apy vectors. To increase the strength of the liver-specific
promoters we produced a collection of chimeric se-
quences by combining these promoters with enhancers
from the albumin and hepatitis B virus genes. Our data
allowed us to categorize the resulting promoters into
three groups: (i) highly active, which are capable of driv-
ing expression at levels similar to that of CMV sequence;
(ii) moderately active, being about 5-fold lower than
CMV; and (iii) weakly active, which can drive expression
at levels 25-fold less than CMV. However, when we ana-
lyzed in vivo the long-term expression of a reporter gene
driven by these constructs we found that the hierarchy of
the promoter strength changed due to a decrease in the
activity of CMV, while most of the liver-specific con-
structs direct stable gene expression possibly because of
their constitutive function. The analysis of extrahepatic
activity of these promoters showed that all of them ex-
hibited marked liver specificity.
We found that Pa1AT constitutes a strong liver-specific
promoter, a finding that has been previously reported
[42]. However, in the context of retroviral plasmid, a
similar 1-antitrypsin promoter region has demonstrated
only a weak activity [43], an observation that could be due
to interference by retroviral LTR in vivo and/or to the
particular transgene used by the authors. From our data
Ealb-Pa1AT, EII-Pa1AT, and Pa1AT are the best regulatory
sequences to ensure a constant and high level of gene
expression in the liver. These promoters appear to be
more suitable for this purpose than EIICMVm, a construct
FIG. 6. Extrahepatic activity of chimeric promoters. (A) 25 g of plasmids
containing the indicated promoters was transferred to mice (n 	 4) in a
PEI/glucose solution. EII-Pa1AT and CMV were used as representative samples
to monitor transfection of the lung. 15 g of DNA extracted from lungs was
loaded on an agarose gel and plasmid bands were detected by Southern blot.
10 ng of CMV-luc (pCMV) plasmid digested with KpnI was carried as positive
control. () Untreated animal. Arrow indicates the position of linear plasmid
DNA. (B) Luciferase (RLU) activity was measured in the same lung extracts after
PEI-mediated transfection with the indicated promoter-containing plasmids.
TABLE 1: Extrahepatic activity of chimeric promoters
Kidney Lung Heart Spleen
RLU luc/mg prota %CMVb RLU luc/mg prota %CMVb RLU luc/mg prota %CMVb RLU luc/mg prota %CMVb
CMV 8.98 
 105  4.73 
 104 100.00 7.20 
 104  8.98 
 103 100.00 3.30 
 104  6.29 
 103 100.00 4.43 
 104  1.08 
 104 100.00
EII-Pa1AT 1.11 
 104  4.50 
 103 1.24 4.18 
 103  1.26 
 103 5.81 3.18 
 103  1.08 
 103 9.63 7.61 
 103  2.52 
 103 17.19
Ealb-Pa1AT 1.03 
 104  2.22 
 103 1.15 1.83 
 103  2.84 
 102 2.54 2.68 
 103  1.57 
 102 8.11 5.05 
 103  4.42 
 102 11.41
EII-Phpx 1.10 
 104  5.45 
 103 1.23 2.21 
 103  5.86 
 102 3.07 7.19 
 102  3.86 
 102 2.18 1.51 
 103  2.97 
 101 3.42
EII-Palb 1.08 
 104  6.40 
 103 1.20 1.35 
 103  6.20 
 102 1.88 9.99 
 102  4.97 
 102 3.03 1.11 
 103  7.52 
 102 2.50
EII-CMVm 1.20 
 105  3.19 
 104 13.40 1.85 
 104  3.09 
 103 25.75 3.41 
 103  1.93 
 103 10.31 1.32 
 104  7.92 
 102 29.93
The plasmids containing the indicated promoters were delivered to mice by the hydrodynamic procedure. Kidney, lung, heart, and spleen were harvested 6 h after DNA infusion and
luciferase activity was determined in the organ extracts.
aRelative light units of luciferase per milligram of total cell proteins.
bPercentage of chimeric promoter activity relative to CMV (promoter and enhancer).
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that, although it has been proposed as a good candidate to
direct gene expression to the hepatic tissue, shows less
specificity than the above-mentioned sequences due to
the presence of the CMVm element (Fig. 2 and [7]).
Our data indicate that the mouse albumin enhancer,
which has been differently reported as very potent or
poorly active [27,44], was active only when combined
with a strong promoter like Pa1AT and not with Palb or
Phpx. The lack of enhancement on these two promoters
could be due to the fact that in our constructs it was
inserted right upstream of the promoter, a position that is
different from the distant situation that it has in the
original gene [20]. With respect to the viral EII, its activity
changes in the context of different promoters since it
seems to stabilize Phpx (which has low activity and shuts
down after 2 weeks) but does not increase the potency at
the steady state of Pa1AT, which is very stable by itself.
It has been hypothesized that viral promoters are not
adequate to direct long-term gene expression in the liver
because of in vivo shutdown as a result of DNA methyl-
ation processes or because of the presence of transcription
factor binding sites whose cognate proteins are not ex-
pressed in the quiescent liver [3,45]. Moreover, some cy-
tokines like interferon  or  are capable of inhibiting the
CMV promoter [46], and consequently CMV transcrip-
tional regulatory sequences would not be appropriate to
construct vectors encoding these cytokines or products
that activate their synthesis. In our hands, the activity of
CMV decays until day 50, an observation that has been
previously reported by Zhang et al. [37] using the same
animal strain, method for transfection of liver cells, and
reporter gene. However, in the mentioned work stabiliza-
tion at a low level of activity was observed after 60 days up
to 6 months [37].
In summary, our work has identified a number of liver-
specific promoter sequences that may be valuable tools
for targeting heterologous genes to the liver when ade-
quate levels of therapeutic proteins need to be produced.
MATERIALS AND METHODS
Plasmid construction. Mouse albumin enhancer and promoter fragments
were isolated by PCR amplification of mouse genomic liver DNA according
to the method of Arrigo et al. [47] and inserted into the pRcCMVluc vector
(pRcCMV backbone, Invitrogen Life Technologies,  luciferase gene (Hin-
dIII–SalI) from pGEMluc, Promega, Madison, WI). Primers used to detect
the albumin enhancer were ATCGATAGATCTTCTGCTTCTCTCAGT and
CCGCGGTCCCCGTGTACTCAT. Primers used for promoter detection
were CCGCGGACAGCTCCAGATGGCAA and AAGCTTAGTGGGGTT-
GATAGGA. The 754-bp enhancer and the 206-bp promoter fragments
were purified from 2% low-melting agarose gel, treated with SstII, ligated,
and redigested with BglII and HindIII. The CMV promoter was removed
from pRcCMVluc with the same enzymes and substituted by the albumin
951-bp enhancer/promoter fragment, resulting in the pRcALBluc vector.
To keep the same backbone in all constructs, promoter and enhancer
sequences were isolated by PCR or enzymatic digestion from the original
plasmids and reinserted into the multicloning site of a promoterless pGL3
basic vector (Promega) to drive firefly luciferase expression. DNA amplifi-
cation was performed with 2.5 units of Pfu (Stratagene, La Jolla, CA), 1 g
of template, and 1 l of each 20 M oligo in a total volume of 100 l. All
inserted sequences were verified by DNA sequencing using RV3 and GL2
primers (Promega). Mouse albumin enhancer (Ealb) and promoter (Palb)
were amplified from pRcALBluc using oligos TCCCCTCGAGGTTCCTA-
GATTACAT, CATACCAGATCTACAGCCACATACT and GCGGAGATCTC-
CAGATGGCAAACA, CGTTACTAGTGGATCCGAGCT, respectively. Hu-
man 1-antitrypsin (Pa1AT) and hemopexin (Phpx) promoters were
isolated from plasmids p1AT305 and pHpx526, respectively [15,18]. Oli-
gos for Pa1AT amplification were GAGATCTGTACCCGCCACCCCCT and
GCCAAGCTTTTCACTGTCCCAGG. Oligos for Phpx isolation were
GGGGCAGATCTCGGGAAAAAGGAGTCT and CTCCCATTTTAAGCTTC-
CTTAGCT. The 227-bp EIIPcore SmaI–XhoI fragment and HBV enhancer II
region (EII) were isolated from pBSCP plasmid [7]. For EII amplification
primers GGACGTCGACCTGAGGTAATTA and CAGCCTCGAGGTACAAA-
GACCTTTAAC were used. The 29-bp Pcore fragment was constructed by
hybridization of two complementary oligos: 5-GGGCATAAATTGGTCT-
GCGCACCAGCACCAA. Nucleotides sufficient for initiation of both pre-
core and pregenomic RNA synthesis are indicated in boldface [34]. The
human CMV promoter–enhancer region spanning position 75 to posi-
tion 675 was used as control [48]. The 104-bp minimum CMV promoter
(position 53 to 51) was isolated from pEIICMVm [7] using CGCGCTC-
GAGGTAGGCGTGTACGGT and CCGAGATCTTCTATGGAGGTCAAA oli-
gos. Created restriction sites are underlined. pGL3 promoter and pGL3
control plasmids (Promega) contain the early SV40 promoter (SV40m) or
the promoter/enhancer region (SV40), respectively. Plasmids containing
the human 1-antitrypsin reporter gene were obtained by substitution of
the HindIII–BamHI luciferase poly(A) sequence in the pGL3-derived vec-
tors by the HindIII–XhoI AAT poly(A) fragment of plasmid pRSV.hAAT.bpA
[38].
Cell cultures, DNA transfections, and luciferase assays. Cells were ob-
tained from ATCC and ECACC and cultured in Dulbecco’s modified Ea-
gle’s medium with 10% fetal bovine serum, penicillin G (100 U/ml),
streptomycin (100 g/ml), and 2 mM L-glutamine at 37°C in 5% CO2/air.
Reagents were purchased from Gibco BRL (Paisley, Scotland). Transient
transfections were performed by the calcium phosphate precipitation
method starting from approximately 2 
 105 cells/well in 12-well dishes
with 1 g of each DNA. Plasmids were purified with the Concert Nucleic
Acid Purification System (Gibco BRL). In all cases, 20 ng of a plasmid that
has the Renilla luciferase gene driven by the SV40 promoter (pRL-SV40;
Promega) was included in the assay to monitor transfection efficiency.
After 32 h, cells were washed with PBS and harvested in 250 l of Passive
Lysis Buffer (PLB; Promega). Firefly and Renilla luciferase activity was
measured in a Berthold Lumat LB 9507 luminometer from 20 l of lysate
using the Dual-Luciferase Reporter Assay System (Promega). The standard
curve equation obtained with purified luciferase (Promega) was generally
ng luc 	 4 
 108 
 RLU  0.0005 (R2 	 0.9952). Total protein concen-
tration was calculated using the Bio-Rad protein assay. The standard curve
equation with BSA (Sigma, Steinheim, Germany) was generally g protein
	 9.5157 
 OD570 nm  3.7505 (R
2 	 0.9902).
In vivo gene delivery and determination of luciferase expression in the
liver and other organs. Plasmid DNAs were delivered into mice organs by
the hydrodynamics method [39,40]. Four to six Balb/C females were used
in each group. Twenty micrograms of DNA in 1.6 ml saline was intrave-
nously injected in a time range of 6 to 7 s. Six hours later mice were
sacrificed and liver, lung, kidney, spleen, and heart were extracted and
mechanically homogenized with an Ultra-Turrax T25 in 1.5 ml (liver) or
0.8 ml (other organs) of PLB (Promega). Samples (0.3 ml) were centrifuged
at 14,000 rpm for 10 min at 4°C and luciferase activity was measured in
concentrated or diluted supernatants. For the long-term study, plasmids
containing the human 1-antitrypsin reporter were purified with the
Endotoxin Free Maxi Kit (Qiagen, Hilden, Germany) and administrated to
C57BL/6 mice (five females per group) as before. Serum levels of AAT were
measured by ELISA [37]. Transfer to the lung of DNA complexed to 22-kDa
linear PEI was performed by intravenous injection of 400 l of a solution
containing 5% glucose, 25 g of DNA, and 7.5 l of 100 mM PEI (amine/
phosphate ratio 10). Four Balb/C mice (7- to 8-week-old females) per group
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were used. Eight hours after injection, animals were sacrificed and lucif-
erase was measured in lungs and other organs.
Southern blot analysis. Homogenized organs (0.5 ml) were mixed with 1
volume of 2
 buffer (10 mM Tris HCl, pH 8, 20 mM EDTA, 2% SDS) with
proteinase K (0.1 mg/ml) and incubated at 55°C for 5 h. The mixture was
then treated three times with phenol:chloroform and DNA was precipi-
tated with 3 M sodium acetate–ethanol and resuspended in 200 l of
deionized water. Fifteen micrograms of total DNA was loaded on a 0.7%
agarose gel after treatment with KpnI and RNase A (25 ng/l). Denatured
DNA was transferred to a nylon membrane (Hybond-N; Amersham Phar-
macia Biotech, Ireland) and bands were detected after hybridization of a
1.7-kb-long digoxigenin–dUTP PCR labeled probe (25 ng/ml) performed
with the PCR DIG Labeling Mix (Roche, Basel, Switzerland), using a sheep
anti-DIG-AP diluted 1:10,000 and the CSPD reagent (Roche). Oligos for
probe preparation were AACATAAAGAAAGGCCCGC and CACTGCAT-
TCTAGTTGTGG, which pair with pGL3 plasmid sequences.
Western blot analysis. Transfected HepG2 cells were lysed as described
above and 7.5 g of protein was loaded on a 12% SDS–polyacrylamide gel
in Laemmli sample buffer. Proteins were separated by electrophoresis and
transferred onto a Hybond-P membrane (Amersham Pharmacia Biotech,
England). The membrane was blocked overnight at 4°C in BL buffer (PBS,
0.05% Tween, 5% nonfat milk) and incubated with 1:1500 diluted goat
anti-firefly luciferase polyclonal antibody (Promega) followed by 1:2000
secondary anti-goat IgG–HRP (Sigma, St. Louis, MO) reaction. Immunore-
active proteins were visualized on exposed Hyperfilm ECL (Amersham)
using the Western Lighting Chemiluminescence Reagent (Perkin–Elmer,
Zaventem, Belgium).
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